<table id="ID444" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3 Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics </caption>
<col width="31%"></col>
<col width="69%"></col>
<tbody>
<tr>
<td align="center" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">Antiretrovirals</content>
<content stylecode="bold">
<br/>
</content>
</td>
<td align="center" stylecode=" Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Toprule" valign="top">The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. <br/>
<br/>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule" valign="middle">
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule" valign="top">o  Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (<linkhtml href="#ID222">12.3</linkhtml>)]. </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule" valign="middle">
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule" valign="top">o  Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with omeprazole may increase toxicity [see clinical Pharmacology (<linkhtml href="#ID222">12.3</linkhtml>)].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule" valign="middle">
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule" valign="top">o   There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Toprule" valign="middle">Rilpivirine-containing products: Concomitant use with omeprazole delayed-release capsule is contraindicated [see Contraindications (<linkhtml href="#ID174">4</linkhtml>)].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule" valign="middle">
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule" valign="middle">Atazanavir: Avoid concomitant use with omeprazole delayed-release capsules. See prescribing information for atazanavir for dosing information. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule" valign="middle">
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule" valign="middle">Nelfinavir: Avoid concomitant use with omeprazole delayed-release capsules. See prescribing information for nelfinavir. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule" valign="middle">
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule" valign="middle">Saquinavir: See the prescribing information for saquinavir for monitoring of potential saquinavir-related toxicities. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule" valign="middle">
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule" valign="middle">Other antiretrovirals: See prescribing information for specific antiretroviral drugs.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="bottom">
<content stylecode="bold">Warfarin </content>
<br/>
</td>
<td align="center" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Increased INR and prothrombin time in patients receiving PPIs, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Monitor INR and prothrombin time and adjust the dose of warfarin, if needed, to maintain target INR range. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="bottom">
<content stylecode="bold">Methotrexate </content>
<br/>
</td>
<td align="center" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Concomitant use of omeprazole with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted [see Warnings and Precautions (<linkhtml href="#ID385">5.11</linkhtml>)].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">A temporary withdrawal of omeprazole may be considered in some patients receiving high-dose methotrexate. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">CYP2C19 </content>
<content stylecode="bold">Substrates </content>
<content stylecode="bold">(</content>
<content stylecode="bold">e</content>
<content stylecode="bold">.</content>
<content stylecode="bold">g</content>
<content stylecode="bold">., </content>
<content stylecode="bold">clopidogrel</content>
<content stylecode="bold">, </content>
<content stylecode="bold">citalopram</content>
<content stylecode="bold">, </content>
<content stylecode="bold">cilostazol</content>
<content stylecode="bold">, </content>
<content stylecode="bold">phenytoin</content>
<content stylecode="bold">, </content>
<content stylecode="bold">diazepam</content>
<content stylecode="bold">) </content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">Clopidogrel</content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition [see Clinical Pharmacology (<linkhtml href="#ID222">12.3</linkhtml>)].  There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel.  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Avoid concomitant use with omeprazole delayed-release capsules. Consider use of alternative anti-platelet therapy [see Warnings and Precautions (<linkhtml href="#ID412">5.6)</linkhtml>].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Citalopram </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Increased exposure of citalopram leading to an increased risk of QT prolongation [see Clinical Pharmacology (<linkhtml href="#ID222">12.3</linkhtml>)].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Limit the dose of citalopram to a maximum of 20 mg per day. See prescribing information for citalopram. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">Cilostazol </content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Increased exposure of one of the active metabolites of cilostazol (3,4-dihydro-cilostazol) [see Clinical Pharmacology (<linkhtml href="#ID222">12.3</linkhtml>)].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Reduce the dose of cilostazol to 50 mg twice daily. See prescribing information for cilostazol. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">Phenytoin </content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Potential for increased exposure of phenytoin. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Monitor phenytoin serum concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for phenytoin. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">Diazepam </content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Increased exposure of diazepam [see Clinical Pharmacology (<linkhtml href="#ID222">12.3</linkhtml>)]. </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Monitor patients for increased sedation and reduce the dose of diazepam as needed. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Digoxin </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Potential for increased exposure of digoxin [see Clinical Pharmacology (<linkhtml href="#ID222">12.3</linkhtml>)].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Monitor digoxin concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See digoxin prescribing information. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">Drugs </content>
<content stylecode="bold">Dependent </content>
<content stylecode="bold">on </content>
<content stylecode="bold">Gastric </content>
<content stylecode="bold">pH </content>
<content stylecode="bold">for </content>
<content stylecode="bold">Absorption </content>
<content stylecode="bold">(</content>
<content stylecode="bold">e</content>
<content stylecode="bold">.</content>
<content stylecode="bold">g</content>
<content stylecode="bold">., </content>
<content stylecode="bold">iron </content>
<content stylecode="bold">salts</content>
<content stylecode="bold">, </content>
<content stylecode="bold">erlotinib</content>
<content stylecode="bold">, </content>
<content stylecode="bold">dasatinib</content>
<content stylecode="bold">, </content>
<content stylecode="bold">nilotinib</content>
<content stylecode="bold">, </content>
<content stylecode="bold">mycophenolate </content>
<content stylecode="bold">mofetil</content>
<content stylecode="bold">, </content>
<content stylecode="bold">ketoconazole</content>
<content stylecode="bold">/</content>
<content stylecode="bold">itraconazole</content>
<content stylecode="bold">) </content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Mycophenolate mofetil (MMF): Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving omeprazole delayed-release capsules and MMF. Use omeprazole delayed-release capsules with caution in transplant patients receiving MMF [see Clinical Pharmacology (<linkhtml href="#ID222">12.3</linkhtml>)].  See the prescribing information for other drugs dependent on gastric pH for absorption.  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">Combination </content>
<content stylecode="bold">Therapy </content>
<content stylecode="bold">with </content>
<content stylecode="bold">Clarithromycin </content>
<content stylecode="bold">and </content>
<content stylecode="bold">Amoxicillin </content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated. Amoxicillin also has drug interactions. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">See <content stylecode="italics">Contraindications</content>
<content stylecode="italics">, </content>
<content stylecode="italics">Warnings </content>and <content stylecode="italics">Precautions </content>in prescribing information for clarithromycin. <br/>See <content stylecode="italics">Drug </content>
<content stylecode="italics">Interactions </content>in prescribing information for amoxicillin.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">Tacrolimus </content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Potential for increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19<content stylecode="italics">. </content>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Monitor tacrolimus whole blood concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">Interactions </content>
<content stylecode="bold">with </content>
<content stylecode="bold">Investigations </content>
<content stylecode="bold">of </content>
<content stylecode="bold">Neuroendocrine </content>
<content stylecode="bold">Tumors </content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors [see Warnings and Precautions (<linkhtml href="#ID381">5.10</linkhtml>), Clinical Pharmacology (<linkhtml href="#ID218">12.2</linkhtml>)].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Temporarily stop omeprazole delayed-release capsules treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">Interaction </content>
<content stylecode="bold">with </content>
<content stylecode="bold">Secretin </content>
<content stylecode="bold">Stimulation </content>
<content stylecode="bold">Test </content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Temporarily stop omeprazole delayed-release capsules treatment at least 14 days before assessing to allow gastrin levels to return to baseline [see Clinical Pharmacology (<linkhtml href="#ID218">12.2</linkhtml>)].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">False </content>
<content stylecode="bold">Positive </content>
<content stylecode="bold">Urine </content>
<content stylecode="bold">Tests </content>
<content stylecode="bold">for </content>
<content stylecode="bold">THC </content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">An alternative confirmatory method should be considered to verify positive results.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Botrule Toprule" valign="middle">
<content stylecode="bold">Other </content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="middle">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Monitor patients to determine if it is necessary to adjust the dosage of these other drugs when taken concomitantly with omeprazole delayed-release capsules. <br/>
</td>
</tr>
</tbody>
</table>